Cytotoxicity and Gene Expression Changes of a Novel Homeopathic Antiseptic Oral Rinse in Comparison to Chlorhexidine in Gingival Fibroblasts.
Masako Fujioka-KobayashiBenoit SchallerMichael A PikosSculean AntonRichard J MironPublished in: Materials (Basel, Switzerland) (2020)
Most available antiseptic solutions available today have strong antibacterial effects, however most also possess major cytotoxic effects on human gingival tissues. The VEGA Oral Care Recovery Kit (StellaLife), previously evaluated in clinical studies, consists of 16 active ingredients that are monographed in the Homeopathic Pharmacopeia of United States (HPUS) and recognized for their accelerated healing properties (reduction in post-op pain). The aim of this study was to compare VEGA to chlorhexidine (CHX) in vitro on gingival fibroblast viability, survival at various concentrations, migration assay, proliferation activity, expression of both regenerative growth factors as well as inflammatory markers, and collagen synthesis. A 10-fold dilution of standard CHX (0.02%) led to cell death, whereas cell viability was significantly better in the VEGA group for all tested parameters. Furthermore, VEGA also induced significantly greater fibroblast migration and proliferation. CHX negatively impacted the cellular inflammatory response of gingival fibroblasts, and also led to a reduction in collagen synthesis (50% decrease). Findings from the present study provide support from basic laboratory experiments that validate the previous clinical studies supporting the use of the VEGA oral rinse on its superior biocompatibility and wound healing properties when compared to CHX.
Keyphrases
- wound healing
- gene expression
- inflammatory response
- cell death
- healthcare
- endothelial cells
- signaling pathway
- dna methylation
- chronic pain
- poor prognosis
- stem cells
- pain management
- tissue engineering
- mesenchymal stem cells
- lipopolysaccharide induced
- palliative care
- mass spectrometry
- extracellular matrix
- bone marrow
- gas chromatography
- health insurance
- liquid chromatography